SCHEMBL16626642

SCHEMBL16626642

CN(Cc1cn(S(=O)(=O)c2cccnc2)c2cc(Oc3cc(Cl)ccc3[N+](=O)[O-])ccc12)C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 12/20 0.35
POLB P06746 1/20 0.34
BCL2 P10415 5/20 0.33
MCL1 Q07820 4/20 0.33
TDP1 Q9NUW8 1/20 0.33
BCL2L1 Q07817 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619016 0.91 HTR6 (0.39) HTR6POLBBCL2MCL1TDP1
SCHEMBL16619019 0.91 HTR6 (0.39) HTR6POLBBCL2MCL1TDP1
SCHEMBL16626641 0.83 POLB (0.38) HTR6POLBBCL2MCL1TDP1
Hydrochloric Acid SCHEMBL16618961 0.82 POLB (0.38) HTR6POLBBCL2MCL1TDP1
SCHEMBL19971347 0.82 POLB (0.37) HTR6POLBBCL2MCL1TDP1
SCHEMBL19971450 0.81 POLB (0.36) HTR6POLBBCL2MCL1TDP1
SCHEMBL16626645 0.80 HTR6 (0.41) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL16626414 0.79 HTR6 (0.39) HTR6POLBPDE4APDE4BPDE4C
SCHEMBL16626621 0.79 HTR6 (0.44) HTR6
SCHEMBL19971435 0.78 HTR6 (0.40) HTR6PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885POLB 4594/4885BCL2 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.